Implications of Viral Resistance to Amantadine in Control of Influenza A
Identifieur interne : 001F48 ( Main/Exploration ); précédent : 001F47; suivant : 001F49Implications of Viral Resistance to Amantadine in Control of Influenza A
Auteurs : Arnold S. Monto [États-Unis] ; Nancy H. Arden [États-Unis]Source :
- Clinical Infectious Diseases [ 1058-4838 ] ; 1992.
Abstract
Antiviral agents are valuable adjuncts to vaccine in the control of type A influenza. Amantadine has been available for many years for prophylaxis and therapy, but there have been concerns about side effects, particularly in the elderly. Thus, the anticipated licensure of rimantadine, an antiviral with the same efficacy as amantadine but with fewer side effects, has been viewed as a major advance. Rimantadine has thus far remained unlicensed, and attention has become focused on antiviral resistance to these drugs, an issue previously recognized but not considered important in decisions concerning drug use. The major implications of antiviral resistance relate to questions of whether there are differences in pathogenicity and transmissibility of resistant influenza type A viruses in comparison with sensitive ones. Resistant viruses have not been found to be more virulent than sensitive ones. The extent to which they may be transmitted or perpetuated has not been established. In light of this situation, it is suggested that drug use not be sharply restricted and that recommendations be periodically reviewed as more definitive data become available. As with any infectious disease, attempts should be made to limit exposure of uninfected individuals to those infected with the influenza A virus, regardless of whether they are receiving an antiviral drug.
Url:
DOI: 10.1093/clinids/15.2.362
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000936
- to stream Istex, to step Curation: 000936
- to stream Istex, to step Checkpoint: 000C99
- to stream Main, to step Merge: 002044
- to stream Main, to step Curation: 001F48
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Implications of Viral Resistance to Amantadine in Control of Influenza A</title><author><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name></author><author><name sortKey="Arden, Nancy H" sort="Arden, Nancy H" uniqKey="Arden N" first="Nancy H." last="Arden">Nancy H. Arden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:47DD79340B8B1B1E8657BD158CC03FBA63495239</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1093/clinids/15.2.362</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-CWTLG8VQ-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000936</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000936</idno><idno type="wicri:Area/Istex/Curation">000936</idno><idno type="wicri:Area/Istex/Checkpoint">000C99</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C99</idno><idno type="wicri:doubleKey">1058-4838:1992:Monto A:implications:of:viral</idno><idno type="wicri:Area/Main/Merge">002044</idno><idno type="wicri:Area/Main/Curation">001F48</idno><idno type="wicri:Area/Main/Exploration">001F48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Implications of Viral Resistance to Amantadine in Control of Influenza A</title><author><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Epidemiology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Reprints or correspondence: Dr. Arnold S. Monto, Department of Epidemiology, University of Michigan, 109 Observatory, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Arden, Nancy H" sort="Arden, Nancy H" uniqKey="Arden N" first="Nancy H." last="Arden">Nancy H. Arden</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Epidemiology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clinical Infectious Diseases</title><idno type="ISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1992-08">1992</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="362">362</biblScope><biblScope unit="page" to="367">367</biblScope></imprint><idno type="ISSN">1058-4838</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Antiviral agents are valuable adjuncts to vaccine in the control of type A influenza. Amantadine has been available for many years for prophylaxis and therapy, but there have been concerns about side effects, particularly in the elderly. Thus, the anticipated licensure of rimantadine, an antiviral with the same efficacy as amantadine but with fewer side effects, has been viewed as a major advance. Rimantadine has thus far remained unlicensed, and attention has become focused on antiviral resistance to these drugs, an issue previously recognized but not considered important in decisions concerning drug use. The major implications of antiviral resistance relate to questions of whether there are differences in pathogenicity and transmissibility of resistant influenza type A viruses in comparison with sensitive ones. Resistant viruses have not been found to be more virulent than sensitive ones. The extent to which they may be transmitted or perpetuated has not been established. In light of this situation, it is suggested that drug use not be sharply restricted and that recommendations be periodically reviewed as more definitive data become available. As with any infectious disease, attempts should be made to limit exposure of uninfected individuals to those infected with the influenza A virus, regardless of whether they are receiving an antiviral drug.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name></region><name sortKey="Arden, Nancy H" sort="Arden, Nancy H" uniqKey="Arden N" first="Nancy H." last="Arden">Nancy H. Arden</name><name sortKey="Monto, Arnold S" sort="Monto, Arnold S" uniqKey="Monto A" first="Arnold S." last="Monto">Arnold S. Monto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:47DD79340B8B1B1E8657BD158CC03FBA63495239
|texte= Implications of Viral Resistance to Amantadine in Control of Influenza A
}}
| This area was generated with Dilib version V0.6.33. |  |